Cargando…

Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome

SIMPLE SUMMARY: Chronic inflammation is known to drive cancer initiation and progression in the liver and other organs. In different genetic mouse models, the role of the pro-inflammatory kinase Tak1 in liver cancer development has been controversial so far. To clarify the role of Tak1 in human hepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ridder, Dirk Andreas, Urbansky, Lana Louisa, Witzel, Hagen Roland, Schindeldecker, Mario, Weinmann, Arndt, Berndt, Kristina, Gerber, Tiemo Sven, Köhler, Bruno Christian, Nichetti, Federico, Ludt, Annekathrin, Gehrke, Nadine, Schattenberg, Jörn Markus, Heinrich, Stefan, Roth, Wilfried, Straub, Beate Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774263/
https://www.ncbi.nlm.nih.gov/pubmed/35053591
http://dx.doi.org/10.3390/cancers14020430
_version_ 1784636295456227328
author Ridder, Dirk Andreas
Urbansky, Lana Louisa
Witzel, Hagen Roland
Schindeldecker, Mario
Weinmann, Arndt
Berndt, Kristina
Gerber, Tiemo Sven
Köhler, Bruno Christian
Nichetti, Federico
Ludt, Annekathrin
Gehrke, Nadine
Schattenberg, Jörn Markus
Heinrich, Stefan
Roth, Wilfried
Straub, Beate Katharina
author_facet Ridder, Dirk Andreas
Urbansky, Lana Louisa
Witzel, Hagen Roland
Schindeldecker, Mario
Weinmann, Arndt
Berndt, Kristina
Gerber, Tiemo Sven
Köhler, Bruno Christian
Nichetti, Federico
Ludt, Annekathrin
Gehrke, Nadine
Schattenberg, Jörn Markus
Heinrich, Stefan
Roth, Wilfried
Straub, Beate Katharina
author_sort Ridder, Dirk Andreas
collection PubMed
description SIMPLE SUMMARY: Chronic inflammation is known to drive cancer initiation and progression in the liver and other organs. In different genetic mouse models, the role of the pro-inflammatory kinase Tak1 in liver cancer development has been controversial so far. To clarify the role of Tak1 in human hepatocellular carcinoma (HCC), we investigated the expression of Tak1 in a large and clinicopathologically well-characterized patient cohort with HCC. In human livers and HCCs, Tak1 is predominantly present in its isoform Tak1A localizing to the cell nucleus. Tak1 is upregulated in HCCs of the diethylnitrosamine mouse model as well as in human HCCs, independent of etiology, and is further induced in distant metastases. Overexpression of the isoform Tak1A in the HCC cell line Huh7 resulted in increased tumor cell migration, whereas overexpression of full-length Tak1 had no significant effect. In human HCCs, high nuclear Tak1 expression is associated with vascular invasion and short overall survival. ABSTRACT: Although knowledge on inflammatory signaling pathways driving cancer initiation and progression has been increasing, molecular mechanisms in hepatocarcinogenesis are still far from being completely understood. Hepatocyte-specific deletion of the MAPKKK Tak1 in mice recapitulates important steps of hepatocellular carcinoma (HCC) development, including the occurrence of cell death, steatohepatitis, dysplastic nodules, and HCCs. However, overactivation of Tak1 in mice upon deletion of its deubiquitinase Cyld also results in steatohepatitis and HCC development. To investigate Tak1 and Cyld in human HCCs, we created a tissue microarray to analyze their expression by immunohistochemistry in a large and well-characterized cohort of 871 HCCs of 561 patients. In the human liver and HCC, Tak1 is predominantly present as its isoform Tak1A and predominantly localizes to cell nuclei. Tak1 is upregulated in diethylnitrosamine-induced mouse HCCs as well as in human HCCs independent of etiology and is further induced in distant metastases. A high nuclear Tak1 expression is associated with short survival and vascular invasion. When we overexpressed Tak1A in Huh7 cells, we observed increased tumor cell migration, whereas overexpression of full-length Tak1 had no significant effect. A combined score of low Cyld and high Tak1 expression was an independent prognostic marker in a multivariate Cox regression model.
format Online
Article
Text
id pubmed-8774263
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87742632022-01-21 Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome Ridder, Dirk Andreas Urbansky, Lana Louisa Witzel, Hagen Roland Schindeldecker, Mario Weinmann, Arndt Berndt, Kristina Gerber, Tiemo Sven Köhler, Bruno Christian Nichetti, Federico Ludt, Annekathrin Gehrke, Nadine Schattenberg, Jörn Markus Heinrich, Stefan Roth, Wilfried Straub, Beate Katharina Cancers (Basel) Article SIMPLE SUMMARY: Chronic inflammation is known to drive cancer initiation and progression in the liver and other organs. In different genetic mouse models, the role of the pro-inflammatory kinase Tak1 in liver cancer development has been controversial so far. To clarify the role of Tak1 in human hepatocellular carcinoma (HCC), we investigated the expression of Tak1 in a large and clinicopathologically well-characterized patient cohort with HCC. In human livers and HCCs, Tak1 is predominantly present in its isoform Tak1A localizing to the cell nucleus. Tak1 is upregulated in HCCs of the diethylnitrosamine mouse model as well as in human HCCs, independent of etiology, and is further induced in distant metastases. Overexpression of the isoform Tak1A in the HCC cell line Huh7 resulted in increased tumor cell migration, whereas overexpression of full-length Tak1 had no significant effect. In human HCCs, high nuclear Tak1 expression is associated with vascular invasion and short overall survival. ABSTRACT: Although knowledge on inflammatory signaling pathways driving cancer initiation and progression has been increasing, molecular mechanisms in hepatocarcinogenesis are still far from being completely understood. Hepatocyte-specific deletion of the MAPKKK Tak1 in mice recapitulates important steps of hepatocellular carcinoma (HCC) development, including the occurrence of cell death, steatohepatitis, dysplastic nodules, and HCCs. However, overactivation of Tak1 in mice upon deletion of its deubiquitinase Cyld also results in steatohepatitis and HCC development. To investigate Tak1 and Cyld in human HCCs, we created a tissue microarray to analyze their expression by immunohistochemistry in a large and well-characterized cohort of 871 HCCs of 561 patients. In the human liver and HCC, Tak1 is predominantly present as its isoform Tak1A and predominantly localizes to cell nuclei. Tak1 is upregulated in diethylnitrosamine-induced mouse HCCs as well as in human HCCs independent of etiology and is further induced in distant metastases. A high nuclear Tak1 expression is associated with short survival and vascular invasion. When we overexpressed Tak1A in Huh7 cells, we observed increased tumor cell migration, whereas overexpression of full-length Tak1 had no significant effect. A combined score of low Cyld and high Tak1 expression was an independent prognostic marker in a multivariate Cox regression model. MDPI 2022-01-15 /pmc/articles/PMC8774263/ /pubmed/35053591 http://dx.doi.org/10.3390/cancers14020430 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ridder, Dirk Andreas
Urbansky, Lana Louisa
Witzel, Hagen Roland
Schindeldecker, Mario
Weinmann, Arndt
Berndt, Kristina
Gerber, Tiemo Sven
Köhler, Bruno Christian
Nichetti, Federico
Ludt, Annekathrin
Gehrke, Nadine
Schattenberg, Jörn Markus
Heinrich, Stefan
Roth, Wilfried
Straub, Beate Katharina
Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome
title Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome
title_full Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome
title_fullStr Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome
title_full_unstemmed Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome
title_short Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome
title_sort transforming growth factor-β activated kinase 1 (tak1) is activated in hepatocellular carcinoma, mediates tumor progression, and predicts unfavorable outcome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774263/
https://www.ncbi.nlm.nih.gov/pubmed/35053591
http://dx.doi.org/10.3390/cancers14020430
work_keys_str_mv AT ridderdirkandreas transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT urbanskylanalouisa transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT witzelhagenroland transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT schindeldeckermario transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT weinmannarndt transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT berndtkristina transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT gerbertiemosven transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT kohlerbrunochristian transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT nichettifederico transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT ludtannekathrin transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT gehrkenadine transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT schattenbergjornmarkus transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT heinrichstefan transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT rothwilfried transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome
AT straubbeatekatharina transforminggrowthfactorbactivatedkinase1tak1isactivatedinhepatocellularcarcinomamediatestumorprogressionandpredictsunfavorableoutcome